Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention

• Status: Completed
• Trial end date: 2017-04-15
• Target enrollment: 0
• Participant gender: Female

Summary

Giving oral Cabergoline or calcium infusion in women at high risk for developing ovarian hyperstimulation syndrome in context of assisted reproductive technologies aiming in its prevention

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Benha University
• Treatments: Cabergoline; Calcium; Calcium, Dietary

Criteria

Inclusion Criteria:

• women undergoing assisted reproductive technologies whom at high risk for developing ovarian hyperstimulation syndrome as with high basal antimullerian hormone ,excess antral follicular count ,high seum estradiol on day of humian choronic gonadotrophin

Exclusion Criteria:women with other endocrinopathy as congenital adrenal hyperplasia , hyperprolactinemia,diabetes

-